Invesco China Health Care Equity Fd.Z
LU2305833829
Invesco China Health Care Equity Fd.Z/ LU2305833829 /
NAV30/05/2024 |
Chg.0.0000 |
Type de rendement |
Focus sur l'investissement |
Société de fonds |
4.0900USD |
0.00% |
reinvestment |
Equity
Sector Health / Pharma
|
Invesco Management ▶ |
Stratégie d'investissement
The objective of the Fund is to achieve long term capital growth. The Fund invests in Chinese healthcare companies listed on the Shanghai or Shenzhen Stock Exchanges, traded via Stock Connect as well as those listed or traded elsewhere, included Qualified Foreign Investors (QFI). The Fund invests in companies which are attractively valued and demonstrate sustainable growth, along with a strong business model and sound balance sheet. For the purposes of the Fund, healthcare companies include (but are not limited to) companies in the sectors of pharmaceuticals, biotechnology, healthcare services and medical technology and supplies.
The Fund may use derivatives (complex instruments) to manage the Fund more efficiently, with the aim of reducing risk, reducing costs and/or generating additional capital or income. The Fund is actively managed and is not constrained by its benchmark, MSCI China A Onshore Health Care Index, which is used for comparison purposes. However, as the benchmark is a suitable proxy for the investment strategy, it is likely that some of the Fund"s holdings are also components of the benchmark. As an actively managed fund, this overlap will change and this statement may be updated from time to time.
Objectif d'investissement
The objective of the Fund is to achieve long term capital growth. The Fund invests in Chinese healthcare companies listed on the Shanghai or Shenzhen Stock Exchanges, traded via Stock Connect as well as those listed or traded elsewhere, included Qualified Foreign Investors (QFI). The Fund invests in companies which are attractively valued and demonstrate sustainable growth, along with a strong business model and sound balance sheet. For the purposes of the Fund, healthcare companies include (but are not limited to) companies in the sectors of pharmaceuticals, biotechnology, healthcare services and medical technology and supplies.
Opérations
Type de rendement: |
reinvestment |
Fonds Catégorie: |
Equity |
Pays: |
China |
Branche: |
Sector Health / Pharma |
Benchmark: |
MSCI China A Onshore Health Care Index |
Début de l'exercice: |
29/02 |
Dernière distribution: |
- |
Banque dépositaire: |
The Bank of New York Mellon SA/NV |
Domicile: |
Luxembourg |
Permission de distribution: |
Austria, Germany, Switzerland |
Gestionnaire du fonds: |
Chris Liu, Kehong Jiang |
Actif net: |
486.11 Mio.
EUR
|
Date de lancement: |
03/03/2021 |
Focus de l'investissement: |
- |
Conditions
Surtaxe d'émission: |
5.00% |
Frais d'administration max.: |
0.75% |
Investissement minimum: |
1,500.00 USD |
Deposit fees: |
0.01% |
Frais de rachat: |
0.00% |
Prospectus simplifié: |
Télécharger (Version imprimée) |
Société de fonds
Société de fonds: |
Invesco Management |
Adresse: |
An der Welle 5, 60322, Frankfurt am Main |
Pays: |
Germany |
Internet: |
www.de.invesco.com
|
Pays
China |
|
65.14% |
Cash |
|
3.09% |
Cayman Islands |
|
3.05% |
Autres |
|
28.72% |
Branches
Pharma/Biotechnology |
|
50.29% |
Healthcare appliances |
|
14.53% |
Healthcare services |
|
3.36% |
Cash |
|
3.09% |
Autres |
|
28.73% |